When technical procurement teams begin running in-house UHPLC/LC-MS audits or comparing third-party laboratory chromatograms across suppliers, two recurring analytical disputes arise: unexpected split or twin peaks on perfectly pure coordination/salt complexes, and massive molecular-weight mismatches between two suppliers quoting the exact same commercial name.

Knowing when a split peak is an on-column mobile-phase artifact versus genuine synthesis impurity—and locking exact sequence nomenclature before ordering—saves weeks of unnecessary batch disputes.

1. Why Pure GHK-Cu Splits into Two Peaks in Standard 0.1% TFA RP-HPLC

Standard reversed-phase peptide QC methods run water/acetonitrile gradients buffered with 0.1% trifluoroacetic acid (TFA, pH ~1.9–2.1) because low pH protonates silanol groups on C18 silica columns and sharpens ordinary linear peptide peaks. However, GHK-Cu (Copper Tripeptide-1, CAS 89030-95-5) is not an ordinary covalent peptide—it is a pH-dependent organometallic coordination complex (C14H22N6O4Cu, complex MW ~401.9 Da; free tripeptide GHK MW 340.38 Da).

  • The Acidic On-Column Dissociation Artifact: When royal-blue GHK-Cu is injected into a pH 2.0 TFA mobile phase, high hydronium concentration protonates the histidine imidazole nitrogen (pKa ~6.0) and terminal amine, partially stripping Cu2+ off the ligand during column elution. The detector then records two peaks: free metal-stripped apo-GHK and residual chelated GHK-Cu—causing inexperienced analysts to misread a >99% pure complex as "65% purity with a 34% impurity peak"!
  • The Proper Orthogonal Method: Assaying the organic ligand backbone under validated method conditions alongside copper stoichiometry / ICP or neutral-pH ammonium-acetate / phosphate LC confirms both ≥ 99% organic tripeptide purity and proper ~2:1 or 1:1 molar complexation spec without acid-induced peak splitting.

2. Other Benign Dual-Peak Artifacts: Halide Counterions & Proline Rotamers

Before rejecting a chromatogram showing a shoulder or early unretained peak, QA reviewers check two additional chemical phenomena:

  • UV-Absorbing Counterions in Small-Molecule Research Catalogs (e.g., Iodide vs. Chloride Salts): In small-molecule pyridinium/quinolinium salts frequently stocked alongside peptides (such as 5-Amino-1MQ iodide vs. chloride), the iodide anion (I−) absorbs strongly at 214–230 nm and elutes near the solvent front (t0), creating a prominent early UV peak entirely separate from the organic cation peak. Switching UV integration wavelength (e.g., 254 nm / 280 nm) or running ion-pair LC-MS immediately distinguishes the benign counterion peak from organic degradation.
  • Proline Cis/Trans Conformational Rotamers (e.g., KPV, BPC-157, Proline-Rich Sequences): Tertiary Xaa-Pro amide bonds have a high rotational energy barrier (~18–21 kcal/mol). At sub-ambient or 25 °C column temperatures under steep UHPLC gradients, interconversion between cis and trans conformers can be slower than chromatographic separation—producing a characteristic bridged doublet or tailing shoulder where both peaks display the exact same monoisotopic m/z in LC-MS. Raising column thermostat temperature to 45 °C – 60 °C collapses true conformers into a single sharp Gaussian peak, whereas real diastereomer impurities (D-amino acid epimerization) remain separated!
Chromatogram Observation Diagnostic LC-MS / Method Check True Synthesis Impurity vs. Method Artifact
Two peaks in GHK-Cu under 0.1% TFA (pH 2.0) Compare neutral pH mobile phase + ESI-MS showing m/z 341.2 [GHK+H]+ vs. 402.1/404.1 Cu isotope doublet Acidic mobile-phase demetallation artifact on C18 column (not degraded raw material)
Early void-volume peak at 214 nm in iodide/bromide salts Inspect UV spectrum at 254/280 nm and extracted ion chromatogram (XIC) UV-active inorganic halide counterion eluting at dead volume t0
Shoulder/doublet on Pro-containing peptide with identical m/z Re-inject at 55 °C column oven temperature vs. 25 °C Coalesces at 55 °C = benign cis/trans proline rotamer; stays split at 55 °C = D/L epimer or isoAsp isomer (true impurity)
Adjacent peak shifted by +16 Da, -18 Da, or deletion mass High-resolution ESI-MS across main and side peaks True chemical impurity (Met/Trp oxidation +16 Da, Aspartimide -18 Da, or SPPS deletion sequence)

3. The "TB-500" Nomenclature Trap: 7-AA Fragment vs. 43-AA Full-Length Thymosin β4

In international peptide trade, no nomenclature ambiguity causes more financial discrepancies than TB-500 (detailed further in TB-500 vs. Tβ4 Nomenclature Checks):

  • Full-Length Synthetic Thymosin β4 (43 Amino Acids, CAS 77591-33-4): Sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH, molecular weight ~4,963.5 Da. ESI-MS displays a characteristic multi-protonated charge envelope ([M+4H]4+ ≈ 1241.9, [M+5H]5+ ≈ 993.7, [M+6H]6+ ≈ 828.3).
  • Short Actin-Binding Fragment (17–23 Heptapeptide, CAS 885340-08-9): Sequence Ac-LKKTETQ-OH (7 Amino Acids), molecular weight ~889.0 Da (or non-acetylated ~847.0 Da). Because synthesizing 7 residues requires ~85% fewer coupling steps than 43 residues, per-gram synthesis cost is dramatically lower—leading unverified brokers to quote "cheap TB-500" without disclosing that the vial contains the 889 Da heptapeptide rather than the 4,963.5 Da 43-mer!

Mandatory Rule for Distributors: Never issue a purchase order for TB-500 vials or blends without writing the exact amino-acid count (43-AA vs. 7-AA), CAS number, and theoretical MW (4,963.5 Da vs. 889.0 Da) on the proforma invoice.

Related sourcing paths